ArticleEnvironmental toxicology2025
Screening for Endocrine Bioactivity Potential of Tobacco Product Chemicals Including Flavor Chemicals.
Article in Environmental toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Adolescence and pregnancy involve elevated levels of hormones (e.g., estrogen, androgen) during which exposure to endocrine disruptors could have long-term developmental and reproductive toxicity (DART) effects. Therefore, the use prevalence and abuse liability of electronic nicotine delivery systems (ENDS) among adolescents and youth, and during pregnancy, raises concerns about possible exposure to endocrine disruptors. In addition, endocrine disruptors have adverse effects on wildlife and environmental health. While many studies focus on carcinogenicity and mutagenicity of tobacco products, research efforts screening chemicals in tobacco products for endocrine disruption potential are few. In this study, we curated 5179 chemicals in tobacco and tobacco smoke, 2803 flavor chemicals, and 156 e-liquid chemicals from literature or openly available databases. We screened the chemicals for endocrine bioactivity using new approach methodologies (NAMs) developed through US Environmental Protection Agency's Endocrine Disruptor Screening Program. The specific NAMs, estrogenic and androgenic pathway models, identified 137 tobacco chemicals, 34 flavor chemicals, and three e-liquid chemicals (Veratraldehyde, (2E)-3-Phenylprop-2-enal, and 2'-Acetonaphthone) as "active," indicating potential endocrine bioactivity. Further, among the tobacco chemicals with endocrine bioactivity potential, 48 were environmentally persistent, 29 bioaccumulative, and 19 both persistent and bioaccumulative. Our findings document many chemicals in tobacco products with potential endocrine bioactivity, which raises concerns for both human and environmental health. These results also underscore the importance of DART potential of tobacco products and flavors. Overall, our study characterizes the endocrine bioactivity potential of tobacco and flavor chemicals and provides a list of chemicals to consider in future ecological and health risk assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.